Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Canadian Cancer Trials Group
American Society of Clinical Oncology
National Cancer Institute (NCI)
Thomas Jefferson University
Stanford University
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
biotx.ai GmbH
St. Jude Children's Research Hospital
Weill Medical College of Cornell University
Pfizer